New insights into cell apoptosis and proliferation: the potential role of vaspin.
Pich K., Respekta N., Dawid M., Mlyczynska E., Kurowska P., Rak A.
Narrative Review, published in J Physiol Pharmacol (2021) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Narrative Review
- Journal
- J Physiol Pharmacol (2021)
- Country
- Poland
- Reported sample size
- —
- Source database
- PubMed
- PMID
- 35377336
- DOI
- 10.26402/jpp.2021.6.02
Abstract (original English)
Vaspin, also known as visceral adipose tissue-derived serine protease inhibitor; expression of this adipokine has been confirmed in many parts of the body like the hypothalamus, pancreas, thyroid gland, ovaries, placenta, and testes, where it may play a crucial role in osteogenesis, steroidogenesis, the formation of blood vessels, and food intake. In addition, there are many studies supporting an interaction between vaspin and cell proliferation and apoptosis, which are crucial processes for maintaining homeostasis of the body. Vaspin has an anti-apoptotic effect in ovarian cells, osteoblasts, macrophages, aortic endothelial cells, hepatocellular carcinoma cells, and cardiomyocytes. On the other hand, vaspin has no effect on apoptosis in aortic smooth muscle cells and cardiomyocytes. Interestingly, vaspin also promotes proliferation in normal and cancerous ovarian cells, pre-adipocytes, hepatocellular carcinoma cells, and bone mesenchymal stem cells, although other studies showed that this adipokine reduces the proliferation of aortic, and vascular smooth muscle cells. Furthermore, vaspin has no effect on the proliferation of chondrocytes, osteoblasts, macrophages, pre-adipocytes, umbilical vein endothelial cells, and coronary artery smooth muscle cells. Dysfunction and dysregulation in the apoptosis/proliferation ratio may lead to cancer development and progression as well as
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is a narrative review: it collects no new patient data and does not systematically appraise evidence quality.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.